title: [Adalimumab induced-inflammatory myopathy in rheumatoid arthritis].
abstract: The application of immunobiologics for the rheumatoid arthritis treatment may present as a rare complication the development of inflammatory myopathy. Until this moment, there have been described in literature only seven cases of inhibitors of tumor necrosis factor induced-myositis. In this paper, we report the case of the patient with 39 years-old with eight years of arthritis rheumatoid and that due to refractory to various immunosuppressive drugs, the adalimumab was introduced, and evolved to dermatomyositis status.
authors.affiliation: Serviço de Reumatologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP), São Paulo.
authors.forename: Fernando Henrique Carlos
authors.initials: FH
authors.lastname: de Souza
authors.forename: Thiago Bitar Morais
authors.initials: TB
authors.lastname: Barros
authors.forename: Mauricio
authors.initials: M
authors.lastname: Levy-Neto
authors.forename: Samuel Katsuyuki
authors.initials: SK
authors.lastname: Shinjo
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009220:Myositis / Q000139:chemically induced*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab